Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syncom Formulation (India)BOM:524470 -2.04%86 PB Ratio is 3.38 as of Aug. 15, 2026, which is 11% above its 10-year median of 3.05. GuruFocus rates BOM:524470 with a GF Score™ of 86/100 and a GF Value™ of ₹20.30 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 919 Drug Manufacturers companies, Syncom Formulation (India) ranks worse than 70.62% on this metric.
The historical rank and industry rank for Syncom Formulation (India)'s PB Ratio or its related term are showing as below:
BOM:524470'
s PB Ratio Range Over the Past 10 Years
Min: 0.34 Med: 3.05 Max: 6.7
Current: 3.38
During the past 13 years, Syncom Formulation (India)'s highest PB Ratio was 6.70. The lowest was 0.34. And the median was 3.05.
BOM:524470's PB Ratio is ranked worse than 70.62% of 919
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs BOM:524470: 3.38
During the past 12 months, Syncom Formulation (India)'s average Book Value Per Share Growth Rate was 21.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 17.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 12.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Syncom Formulation (India) was 17.50% per year. The lowest was -17.20% per year. And the median was 7.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Syncom Formulation (India) PB Ratio Related Terms
Syncom Formulation (India) PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Syncom Formulation (India)'s PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syncom Formulation (India) PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Syncom Formulation (India)'s PB Ratio distribution charts can be found below:
* The bar in red indicates where Syncom Formulation (India)'s PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Syncom Formulation (India) (BOM:524470) has a PB Ratio of 3.38 as of Aug. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Syncom Formulation (India) and its competitors. This is 11% above median its historical median of 3.05. Over the past decade, Syncom Formulation (India)'s PB Ratio has ranged from 0.34 to 6.70. According to the industry distribution chart, Syncom Formulation (India) ranks #649 out of 919 companies in the Drug Manufacturers industry, placing it in the top 70.6%.
Is Syncom Formulation (India)'s PB Ratio too high?
Syncom Formulation (India)'s current PB Ratio of 3.38 is 11% above median its 10-year median of 3.05. Over the past 10 years, this metric has ranged from a low of 0.34 to a high of 6.70. The Drug Manufacturers industry median PB Ratio is 1.98. Syncom Formulation (India)'s value of 3.38 is 70.7% above this industry median. Based on the distribution chart, Syncom Formulation (India) ranks #649 out of 919 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Syncom Formulation (India) has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Syncom Formulation (India) ranks #649 out of 919 companies for PB Ratio. This places Syncom Formulation (India) in the lower half of its industry. The industry median PB Ratio is 1.98. Syncom Formulation (India)'s value of 3.38 is 70.7% above this benchmark. Historically, Syncom Formulation (India)'s own PB Ratio has ranged from 0.34 to 6.70 over the past decade. While the company's 10-year median is 3.05 vs. the industry median of 1.98, Syncom Formulation (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 919 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syncom Formulation (India)'s current PB Ratio of 3.38 is 70.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Syncom Formulation (India) and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syncom Formulation (India)'s current PB Ratio is 3.38, which is 11% above median its own 10-year median of 3.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹20.30, compared to a current price of ₹14.92 — trading 26.5% below its estimated fair value. The current PB Ratio is 3.38, which is 11% above median its 10-year median of 3.05 and 70.7% above the Drug Manufacturers industry median of 1.98. Syncom Formulation (India)'s overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current PB Ratio is 3.38 as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?
Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued.
The current stock price of ₹14.92 is trading 26.5% below its estimated GF Value™ of ₹20.30.
GuruFocus considers Syncom Formulation (India) to be Modestly Undervalued.
Key valuation signals for BOM:524470:
PB Ratio: 3.38 (11% above median its 10-year median of 3.05)
GF Value™: ₹20.30 vs. price of ₹14.92 (26.5% below fair value)
Industry Position: 70.7% above the Drug Manufacturers median (#649 of 919)
No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
86GF Score
Get the complete analysis for BOM:524470
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524470 has been successfully added to your 
